Better Patient Outcomes.
Better Safety Profiles.
Innovative Pipeline
We are developing a portfolio of internally discovered next generation innovative therapies using integrated chemical genomics-driven approaches and proprietary chemistries for diseases with unmet needs.
We have multiple products in our pipeline at various stages of development for chronic conditions in large therapeutic areas.
Program
- Brilaroxazine
Serotonin / dopamine modulator (NCE) - RP1208
Triple reuptake inhibitor (NCE)
Prioritized Target Indications*
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- ADHD
- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis
- Psoriasis (topical gel)
- Depression
- Obesity
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- ADHD
- Pulmonary Arterial Hypertension
- Idiopathic Pulmonary Fibrosis
- Psoriasis (topical gel)
- Depression
- Obesity
*Opportunity to expand into other indications including Parkinson’s Psychosis and Alzheimer’s (Psychosis/agitation)